Risk Evaluation and Mitigation
"Risk Evaluation and Mitigation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Strategies required by the US Food and Drug Administration (FDA) Amendments Act of 2007 when a question exists as to whether the benefits of a drug outweigh its risks. These constitute a safety plan with several potential components, including a medication guide, a communication plan, elements to ensure safe use and an implementation system to help guide the prescribers, pharmacists and patients.
| Descriptor ID |
D000073938
|
| MeSH Number(s) |
N04.452.871.758 N06.850.505.715.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Risk Evaluation and Mitigation".
Below are MeSH descriptors whose meaning is more specific than "Risk Evaluation and Mitigation".
This graph shows the total number of publications written about "Risk Evaluation and Mitigation" by people in this website by year, and whether "Risk Evaluation and Mitigation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Risk Evaluation and Mitigation" by people in Profiles.
-
"It was close enough, but it wasn't close enough": A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care. Contraception. 2021 07; 104(1):67-72.
-
Federal, state, and institutional barriers to the expansion of medication and telemedicine abortion services in Ohio, Kentucky, and West Virginia during the COVID-19 pandemic. Contraception. 2021 07; 104(1):111-116.
-
An introduction to risk evaluation and mitigation strategies. Contraception. 2021 07; 104(1):4-7.
-
Changes needed in Medicaid coverage and reimbursement to meet an evolving abortion care landscape. Contraception. 2021 07; 104(1):20-23.
-
The future of abortion is now: Mifepristone by mail and in-clinic abortion access in the United States. Contraception. 2021 07; 104(1):38-42.
-
Abortion exceptionalism and the mifepristone REMS. Contraception. 2021 07; 104(1):8-11.
-
The spatio-temporal distribution of COVID-19 infection in England between January and June 2020. Epidemiol Infect. 2021 03 08; 149:e73.
-
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA. 2019 Feb 19; 321(7):676-685.
-
The Food and Drug Administration Should Mandate Risk Evaluation and Mitigation Strategies Training for All Opioids. Anesth Analg. 2018 04; 126(4):1413-1417.